CIViC Evidence Items

265 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
C	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Osimertinib	Planchard et al., 2015
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Neratinib	Shimamura et al., 2006
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Li et al., 2008
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Cha et al., 2012
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Canertinib	Li et al., 2008
D	EGFR	E746_A750del	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Cross et al., 2014
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Li et al., 2008
C	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Pao et al., 2004
C	EGFR	S768I	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Leventakos et al., 2016
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Cancer	Gefitinib	Endoh et al., 2006
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Cancer	Erlotinib	Ramalingam et al., 2011
C	EGFR	E746_T751>I	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Pao et al., 2004
C	EGFR	L747P	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Wu et al., 2011
C	EGFR	V774M	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Wu et al., 2011
C	EGFR	K806E	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
C	EGFR	N826Y	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
C	EGFR	N842S	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
C	EGFR	T847I	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
C	EGFR	V851I	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
D	EGFR	L838V	Predictive	Supports	Resistance	Cancer	Gefitinib,Erlotinib	Kancha et al., 2009
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Li et al., 2008
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Harada et al., 2011
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	De Grève et al., 2016
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Konduri et al., 2016
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Small Cell Carcinoma	Erlotinib	Cross et al., 2014
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Cross et al., 2014
B	EGFR	Rare Exon 18-21 Mutation	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Wu et al., 2011
C	EGFR	T790M	Predictive	Does Not Support	Sensitivity/Response	Pancreatic Adenocarcinoma	Osimertinib	Cecchini et al., 2017
C	EGFR	G719A	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Locatelli-Sanchez et al., 2013
C	EGFR	R705K	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Locatelli-Sanchez et al., 2013
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Urata et al., 2016
C	EGFR	Rare Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Urata et al., 2016
E	EGFR	V441F	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab,Cetuximab	Strickler et al., 2018
B	EGFR	Exon 20 Insertion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Fang et al., 2019
C	EGFR	A763_Y764insFQEA	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Fang et al., 2019
D	EGFR	R222C	Functional	Supports	Gain of Function			Ng et al., 2018
D	EGFR	E114K	Functional	Supports	Unaltered Function			Ng et al., 2018
C	EGFR	Amplification AND EGFR::SEPTIN14 Fusion	Predictive	Supports	Sensitivity/Response	Colon Adenocarcinoma	Erlotinib	Li et al., 2020
E	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Staurosporine	Ai et al., 2014
D	EGFR	VIII	Predictive	Supports	Sensitivity/Response	Brain Glioma	Nimotuzumab	Nitta et al., 2016
C	EGFR	T790M AND EGFR Exon 19 Deletion AND EGFR C797S	Predictive	Supports	Resistance	Lung Adenocarcinoma	Osimertinib	Yu et al., 2015
C	EGFR	T790M AND EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Osimertinib	Yu et al., 2015
B	EGFR	Expression	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Saltz et al., 2004
C	EGFR	E746G	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Klughammer et al., 2016
C	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Pao et al., 2004
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Ray et al., 2016
C	EGFR	N771_P772insL	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Fang et al., 2019
D	EGFR	R252C	Functional	Supports	Unaltered Function			Ng et al., 2018
C	EGFR	G719A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Douillard et al., 2010
D	EGFR	G719S	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Kancha et al., 2009

Page 5 of 6

Previous Next